https://www.selleckchem.com/pr....oducts/baricitinib-l
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial study recently demonstrated that administration of high doses of omega-3 fatty acids confers cardiovascular benefit in high-risk patients with the modest hypertriglyceridemia. This provided optimism for a therapeutic area that has challenged the field of cardiovascular prevention for 2 decades. However, it raises a number of questions including understanding the mechanism underscoring this benefit, how best to use these therapies and whether sim
Like
Comment
Share
